<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310777</url>
  </required_header>
  <id_info>
    <org_study_id>C-10-040</org_study_id>
    <secondary_id>2010-024512-34</secondary_id>
    <nct_id>NCT01310777</nct_id>
  </id_info>
  <brief_title>Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine
      in lowering intraocular pressure (IOP) relative to each of its individual active components
      in patients with open-angle glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consisted of 7 visits conducted during 2 sequential phases: the
      screening/eligibility phase, which included a screening visit and 2 eligibility visits, and a
      treatment phase, which included 4 on-therapy visits conducted at Week 2, Week 6, Month 3, and
      Month 6 (or early exit). Following washout of any IOP-lowering medication, subjects who met
      all inclusion/exclusion criteria at both eligibility visits and who had IOP measurements
      within the specified range during this period were randomized to 1 of 3 study drug groups:
      Brinz/Brim, Brinz, or Brim.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Diurnal IOP Change From Baseline at Month 3</measure>
    <time_frame>Baseline (Day 1), Month 3</time_frame>
    <description>Mean Diurnal IOP Change from Baseline at Month 3 (ie, the subject IOP change from baseline averaged over the 9 AM, + 2 h, and + 7 h time points at Month 3) was measured by Goldmann applanation tonometry. The study drug was instilled approximately 15 minutes after conducting the 9AM IOP measurement. One eye from each subject was chosen as the study eye, and only data for the study eye were used for the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">771</enrollment>
  <condition>Open-Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Brinz/Brim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brinz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension</intervention_name>
    <arm_group_label>Brinz/Brim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide 1% ophthalmic suspension</intervention_name>
    <arm_group_label>Brinz</arm_group_label>
    <other_name>AZOPTâ„¢</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine tartrate 0.2% ophthalmic solution</intervention_name>
    <arm_group_label>Brim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with open angle glaucoma or ocular hypertension, and, in the opinion of the
             Investigator, are insufficiently controlled on monotherapy or are currently on
             multiple IOP-lowering medications.

          -  Meet qualifying IOP entry criteria.

          -  Able to understand and sign an informed consent form.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Women of childbearing potential if pregnant, test positive for pregnancy at Screening
             Visit, breastfeeding, or not in agreement to use adequate birth control methods to
             prevent pregnancy throughout the study.

          -  Severe central visual field loss.

          -  Best corrected visual acuity (BCVA) score worse than 55 ETDRS letters (20/80 Snellen
             equivalent).

          -  Chronic, recurrent or severe inflammatory eye disease.

          -  Ocular trauma within the preceding 6 months.

          -  Ocular infection or ocular inflammation within the preceding 3 months.

          -  Clinically significant or progressive retinal disease.

          -  Other ocular pathology.

          -  Intraocular surgery within the 6 months prior to entry.

          -  Ocular laser surgery within the 3 months prior to entry.

          -  Any abnormality preventing reliable applanation tonometry.

          -  Any other conditions, including severe illness, which would make the subject, in the
             opinion of the Investigator, unsuitable for the study.

          -  Recent use of high-dose (&gt;1 gram daily) salicylate therapy.

          -  Recent, current, or anticipated treatment with any medication that augments adrenergic
             responses, or precludes use of an alpha-adrenergic agonist.

          -  Concurrent use of glucocorticoid medications administered by any route.

          -  Other protocol-specified exclusion crtieria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Teague, Sr. Clinical Manager</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <results_first_submitted>January 24, 2014</results_first_submitted>
  <results_first_submitted_qc>January 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2014</results_first_posted>
  <last_update_submitted>January 24, 2014</last_update_submitted>
  <last_update_submitted_qc>January 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-Angle glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <keyword>OAG</keyword>
  <keyword>OHT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 63 investigational centers in the Asia-Pacific region, the European Union, Latin America and Caribbean nations, and the United States.</recruitment_details>
      <pre_assignment_details>Of the 771 enrolled, 211 subjects did not meet inclusion/exclusion criteria and were exited from the study as screen failures prior to randomization. This reporting group includes all randomized subjects (560).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Brinz/Brim</title>
          <description>Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Brinz</title>
          <description>Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months</description>
        </group>
        <group group_id="P3">
          <title>Brim</title>
          <description>Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="192"/>
                <participants group_id="P3" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient's Decision Unrelated to AE</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadequate Control of IOP</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This reporting group includes all randomized subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Brinz/Brim</title>
          <description>Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Brinz</title>
          <description>Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Brim</title>
          <description>Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="193"/>
            <count group_id="B2" value="192"/>
            <count group_id="B3" value="175"/>
            <count group_id="B4" value="560"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Diurnal IOP Change From Baseline at Month 3</title>
        <description>Mean Diurnal IOP Change from Baseline at Month 3 (ie, the subject IOP change from baseline averaged over the 9 AM, + 2 h, and + 7 h time points at Month 3) was measured by Goldmann applanation tonometry. The study drug was instilled approximately 15 minutes after conducting the 9AM IOP measurement. One eye from each subject was chosen as the study eye, and only data for the study eye were used for the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).</description>
        <time_frame>Baseline (Day 1), Month 3</time_frame>
        <population>The intent-to-treat (ITT) analysis set included all subjects who received study drug and completed at least 1 scheduled on-therapy study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Brinz/Brim</title>
            <description>Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Brinz</title>
            <description>Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Brim</title>
            <description>Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Diurnal IOP Change From Baseline at Month 3</title>
          <description>Mean Diurnal IOP Change from Baseline at Month 3 (ie, the subject IOP change from baseline averaged over the 9 AM, + 2 h, and + 7 h time points at Month 3) was measured by Goldmann applanation tonometry. The study drug was instilled approximately 15 minutes after conducting the 9AM IOP measurement. One eye from each subject was chosen as the study eye, and only data for the study eye were used for the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).</description>
          <population>The intent-to-treat (ITT) analysis set included all subjects who received study drug and completed at least 1 scheduled on-therapy study visit.</population>
          <units>millimeters of mercury (mmHg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="0.22"/>
                    <measurement group_id="O2" value="-6.5" spread="0.23"/>
                    <measurement group_id="O3" value="-6.4" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study (1 year, 8 months). An AE was defined as any untoward medical occurrence in a subject who was administered a study medication, regardless of causal relationship with the medication.</time_frame>
      <desc>This reporting group includes all subjects exposed to study drug. Reports of AEs were obtained through solicited and spontaneous comments from the study subjects, and through observations by the study Investigator as outlined in the study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Brinz/Brim</title>
          <description>Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Brinz</title>
          <description>Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months</description>
        </group>
        <group group_id="E3">
          <title>Brim</title>
          <description>Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matt Walker, PhD, Clinical Project Lead</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

